Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Approval entities : I-mab save search
I-Mab Announces Approval from China CDE to Initiate Phase 3 Registrational Study of Lemzoparlimab in Combination with Azacitidine in Higher-Risk Myelodysplastic Syndrome
Published: 2022-09-13 (Crawled : 13:20) - biospace.com/
IMAB | $1.805 0.28% 0.28% 110K
|
Health Technology
|
| O: -2.33%
H: 0.72%
C: -0.73%
approval china study
I-Mab Announces IND Approval from China NMPA for Phase 2 Clinical Trial of Enoblituzumab in Combination with Pembrolizumab in Solid Tumors
Published: 2021-12-27 (Crawled : 14:00) - biospace.com/
MGNX | $15.7 -3.27% -3.38% 520K
|
Health Technology
|
| O: -0.75%
H: 1.28%
C: -2.84%
IMAB | $1.805 0.28% 0.28% 110K
|
Health Technology
|
| O: -0.49%
H: 2.25%
C: -0.79%
phase 2 solid tumors trial approval china
I-Mab Receives IND Approval for Phase 1 Clinical Trial of Bispecific Antibody TJ-CD4B in Solid Tumors in China
Published: 2021-12-15 (Crawled : 15:30) - biospace.com/
IMAB | $1.805 0.28% 0.28% 110K
|
Health Technology
|
| O: -11.41%
H: 8.08%
C: 7.32%
solid tumors trial approval phase 1 china antibody phase 2
I-Mab Announces IND Approval for Phase 2 Clinical Trial of Efineptakin Alfa in Combination with PD-1 Therapy in China
Published: 2021-10-18 (Crawled : 12:00) - prnewswire.com
IMAB | $1.805 0.28% 0.28% 110K
|
Health Technology
|
| O: -1.19%
H: 4.34%
C: 2.66%
phase 2 china therapy trial approval
I-Mab Announces IND Approval by FDA to Initiate Phase 1 Study for Protollin for the Treatment of Alzheimer's Disease
Published: 2021-07-30 (Crawled : 12:15) - prnewswire.com
IMAB | $1.805 0.28% 0.28% 110K
|
Health Technology
|
| O: -2.28%
H: 0.0%
C: 0.0%
disease alzheimer treatment fda phase 1 approval phase 2 phase 3 alzheimer’s alzheimer's disease alzheimer's
I-Mab Announces China NMPA Approval for Phase 1b Trial of Felzartamab in Systemic Lupus Erythematosus
Published: 2021-06-25 (Crawled : 13:00) - biospace.com/
MOR | News | $18.07 0.17% 0.17% 130K
|
Health Technology
|
| O: 2.89%
H: 0.23%
C: -0.55%
IMAB | $1.805 0.28% 0.28% 110K
|
Health Technology
|
| O: -3.4%
H: 3.67%
C: -0.65%
phase 1 china trial approval lupus phase 1b phase 2b
Scilex Holding, a Subsidiary of Sorrento, Has Received From FDA a sNDA Approval for ZTlido® Label Expansion
Published: 2021-04-09 (Crawled : 20:00) - globenewswire.com
SRNE | $0.015 -8.85% 56K
|
Health Technology
| Email alert
Add to watchlist
IMAB | $1.805 0.28% 0.28% 110K
|
Health Technology
| Email alert
Add to watchlist
fda expansion approval
I-Mab and ABL Bio Receive US FDA Approval to Initiate Phase 1 Trial of Bispecific Antibody TJ-CD4B/ABL111 in Patients with Advanced or Metastatic Solid Tumors
Published: 2021-03-30 (Crawled : 12:15) - globenewswire.com
IMAB | $1.805 0.28% 0.28% 110K
|
Health Technology
|
| O: 3.45%
H: 4.76%
C: 2.74%
fda solid tumors phase 1 fda approval antibody trial approval phase 3 phase 2
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.